Yahoo · Sep 10, 2026
Biopharmaceutical Leader Kiniksa Poised To Hit New Buy Point After Big Revenue Beat
Biotech leader Kiniksa stock is poised to hit a fresh buy point after shares soared 25% in response to better-than-expected sales numbers.
KN
NASDAQ · KNSA
Kiniksa Pharmaceuticals, Ltd.
Healthcare · Biotechnology
$77.62
Up+$0.99 (+1.27%)
Updated Sep 17, 2026, 6:09 PM
SID Score
5.5/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 3B
- P/E ratio
- 83.96
- Dividend yield
- 0.00%
- 52-week range
- $35.20 – $82.94
- Volume
- 553.9K
- Avg. volume
- 427.35K
Price performance
KNSA price history
1M range · 0 trading sessions · Daily adjusted prices
KNSA does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest KNSA news
The latest Smart Investors Daily articles mentioning KNSA.
Stock researchCompany · Overview
KNSA research
Overview
Company profile and research snapshot.
Company profile
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $51.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 30, 2026 | Goldman Sachs | Buy | — |
| Jul 29, 2026 | Citigroup | Buy | — |
| Jul 29, 2026 | Wedbush | Outperform | — |
| Jul 29, 2026 | Canaccord Genuity | Buy | — |
| Jul 29, 2026 | JP Morgan | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 4, 2026
Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
LONDON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026 at 8:45 a.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximate
ChartMill · Aug 29, 2026
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Combines High Growth Momentum with a Breakout Setup
Kiniksa Pharmaceuticals (KNSA) combines strong high-growth momentum with a top technical setup, featuring 58.9% revenue growth and a breakout pattern near resistance.
ChartMill · Aug 26, 2026
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Shows Strong Growth and a Technical Setup for a Potential Breakout
Kiniksa Pharmaceuticals (KNSA) combines strong growth, profitability, and a healthy balance sheet with a bullish technical breakout setup near resistance.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
